Mention recent pharmacologic advances in alopecia areata and their mechanism of action.

• A. Biologics targeting TNF-alpha have clear proven efficacy.
• B. JAK inhibitors such as tofacitinib and ruxolitinib show promise by inhibiting JAK-STAT signaling and reducing autoimmune attack on hair follicles.
• C. Finasteride is the main new therapy.
• D. Platelet-rich plasma is the only approved option.

Answer: (B)

Autoimmune attack on hair follicles in alopecia areata is driven by cytokine signaling that relies on the JAK-STAT pathway, so therapies that block this signaling can dampen the attack and permit hair regrowth. JAK inhibitors such as tofacitinib (JAK1/3) and ruxolitinib (JAK1/2) work by preventing phosphorylation of STAT transcription factors. This stops the downstream effects of key cytokines—like IFN-γ and IL-15—that normally promote cytotoxic T cell activity and inflammation around the follicle. With this signaling blocked, the immune attack on the hair follicle lessens, helping restore the follicle’s immune privilege and allowing the hair growth cycle to resume.

In practice, these drugs have shown meaningful hair regrowth in many patients with various severities of alopecia areata, illustrating how targeting this specific immune pathway can alter the disease course. It’s important to note that while promising, JAK inhibitors carry safety considerations such as infection risk, cytopenias, lipid changes, and potential thrombotic or malignancy concerns, so use requires careful monitoring.

Why the other statements aren’t as fitting: therapies targeting TNF-α haven’t demonstrated clear, consistent benefit in alopecia areata. Finasteride targets androgen pathways and is used mainly for androgenetic alopecia, not autoimmune AA. Platelet-rich plasma is not an approved, universally effective therapy for alopecia areata, and claiming it as the only approved option isn’t accurate.